Alnylam Pharmaceuticals
NEWS
The U.S. FDA approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
Two Phase III studies of lumasiran showed a significant reduction in urinary oxalate excretion in patients of all ages with PH1. Know more about it here.
Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
The results of Lumasiran were presented at the European Renal Association-European Dialysis and Transplant Association International Congress.
Alnylam Pharmaceuticals’ lumasiran for a chronic kidney stone disease was granted Priority Review status by the U.S. Food and Drug Administration. It will have a target action date of December 3, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
“Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies,” said Nicholas Galakatos, global head of Blackstone Life Sciences.
At least three different biotech companies are working on two ACE2-related drugs to find a solution to the COVID-19 pandemic.
JOBS
IN THE PRESS